MEP10808A - Solid drug for oral use - Google Patents

Solid drug for oral use

Info

Publication number
MEP10808A
MEP10808A MEP-108/08A MEP10808A MEP10808A ME P10808 A MEP10808 A ME P10808A ME P10808 A MEP10808 A ME P10808A ME P10808 A MEP10808 A ME P10808A
Authority
ME
Montenegro
Prior art keywords
pharmaceutically acceptable
oral use
solid drug
solid
dysuria
Prior art date
Application number
MEP-108/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP10808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MEP10808A publication Critical patent/MEP10808A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-108/08A 2002-12-16 2003-12-11 Solid drug for oral use MEP10808A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16
PCT/JP2003/015837 WO2004054574A1 (ja) 2002-12-16 2003-12-11 経口固形医薬

Publications (1)

Publication Number Publication Date
MEP10808A true MEP10808A (en) 2010-06-10

Family

ID=32588229

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-108/08A MEP10808A (en) 2002-12-16 2003-12-11 Solid drug for oral use
MEP-2008-108A ME00076B (me) 2002-12-16 2003-12-11 Lijek u čvrstom obliku za oralnu primjenu

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-108A ME00076B (me) 2002-12-16 2003-12-11 Lijek u čvrstom obliku za oralnu primjenu

Country Status (24)

Country Link
US (2) US20060018959A1 (pt)
EP (2) EP2402010A1 (pt)
JP (1) JP4633469B2 (pt)
KR (2) KR101072909B1 (pt)
CN (2) CN101069685B (pt)
AU (1) AU2003289320C1 (pt)
BR (1) BR0317349A (pt)
CA (1) CA2507002C (pt)
EA (1) EA008196B1 (pt)
ES (1) ES2544560T3 (pt)
HK (2) HK1107768A1 (pt)
HR (1) HRP20050544B1 (pt)
IL (1) IL169040A (pt)
IS (1) IS7929A (pt)
ME (2) MEP10808A (pt)
MX (1) MXPA05006513A (pt)
NO (1) NO20053467L (pt)
NZ (1) NZ540664A (pt)
PL (1) PL220457B1 (pt)
RS (1) RS58025B1 (pt)
TW (2) TWI325318B (pt)
UA (2) UA85359C2 (pt)
WO (1) WO2004054574A1 (pt)
ZA (1) ZA200504613B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5004215B2 (ja) * 2004-03-05 2012-08-22 キッセイ薬品工業株式会社 神経障害に伴う過活動膀胱の予防または治療用医薬組成物
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
CL2008000727A1 (es) * 2007-03-13 2008-10-17 Takeda Pharmaceutical Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
EP2595607A2 (de) 2010-07-23 2013-05-29 Ratiopharm GmbH Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
ES2492673T3 (es) 2010-12-23 2014-09-10 Sandoz Ag Formas cristalinas de un ingrediente farmacéutico activo
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
US20140243383A1 (en) * 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
EP2744498A4 (en) * 2012-02-16 2014-12-03 Teva Pharma N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF
RS57795B1 (sr) 2012-07-16 2018-12-31 Fibrogen Inc Kristalni oblici inhibitora prolil hidroksilaze
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN105142633A (zh) 2013-03-26 2015-12-09 橘生药品工业株式会社 西洛多辛苦味被掩蔽的口服给药制剂
CN110448537A (zh) 2013-06-06 2019-11-15 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
KR102206104B1 (ko) 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
EP0600675B1 (en) 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
KR100232297B1 (ko) 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
AU2001256714A1 (en) * 2000-05-15 2001-11-26 Kissei Pharmaceutical Co. Ltd. Water-based liquid preparation
DK1413331T3 (da) * 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR20030076715A (ko) * 2001-03-01 2003-09-26 그레랑 파마수티컬 가부시키가이샤 페노피브라이트 함유 조성물
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
WO2004054574A1 (ja) 2004-07-01
TW200944200A (en) 2009-11-01
AU2003289320A1 (en) 2004-07-09
PL377495A1 (pl) 2006-02-06
UA84694C2 (ru) 2008-11-25
EP1574215A4 (en) 2009-07-01
JPWO2004054574A1 (ja) 2006-04-20
CA2507002A1 (en) 2004-07-01
ZA200504613B (en) 2006-08-30
CN101069685A (zh) 2007-11-14
MXPA05006513A (es) 2005-09-08
ES2544560T3 (es) 2015-09-01
UA85359C2 (ru) 2009-01-12
AU2003289320C1 (en) 2018-09-06
EP2402010A1 (en) 2012-01-04
KR101077061B1 (ko) 2011-10-26
NZ540664A (en) 2007-09-28
TW200418457A (en) 2004-10-01
EA008196B1 (ru) 2007-04-27
RS58025B1 (sr) 2019-02-28
NO20053467L (no) 2005-07-15
RS20050470A (en) 2007-09-21
KR101072909B1 (ko) 2011-10-17
EA200500985A1 (ru) 2005-12-29
EP1574215B1 (en) 2015-07-15
BR0317349A (pt) 2005-11-16
KR20050084316A (ko) 2005-08-26
HK1085131A1 (en) 2006-08-18
EP1574215A1 (en) 2005-09-14
CN100339078C (zh) 2007-09-26
JP4633469B2 (ja) 2011-02-16
TWI325318B (en) 2010-06-01
IL169040A (en) 2013-04-30
CN1726028A (zh) 2006-01-25
CN101069685B (zh) 2011-12-14
IS7929A (is) 2005-07-01
CA2507002C (en) 2012-09-18
HRP20050544B1 (hr) 2017-12-01
ME00076B (me) 2011-02-10
AU2003289320B2 (en) 2008-08-21
HRP20050544A2 (en) 2006-09-30
US20120064154A1 (en) 2012-03-15
US20060018959A1 (en) 2006-01-26
KR20100133024A (ko) 2010-12-20
TWI382838B (zh) 2013-01-21
HK1107768A1 (en) 2008-04-18
PL220457B1 (pl) 2015-10-30

Similar Documents

Publication Publication Date Title
MEP10808A (en) Solid drug for oral use
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
JP2010523477A5 (pt)
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
ES2384333T3 (es) Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
CY1110184T1 (el) Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
EA200600377A1 (ru) Новая композиция
JP2005187328A (ja) イブプロフェン含有解熱鎮痛組成物、及び感冒薬
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
KR20150117497A (ko) 테노포비르디소프록실푸마레이트 필름형 제제 및 그 제조방법
EA200601285A1 (ru) Нераспадающаяся твёрдая композиция для перорального применения с высокой дозой растворимых в воде лекарственных средств
ES2550790T3 (es) Agente terapéutico para el dolor producido por cáncer
CA2982460C (en) Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
UA144735U (uk) Спосіб лікування хвороб органів травлення
PL440759A1 (pl) Nowe pochodne kwasu ursolowego, sposób ich otrzymywania, zastosowanie medyczne oraz kompozycja farmaceutyczna
ATE270T1 (de) Neue n1-benzoyl-n2-phenyl-1,3-diaminopropan-2-ole und ihre salze; verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
TR201723198A2 (tr) Erdostein ve askorbik asit ihtiva eden kompozisyonlar.